Contact Us

Andarix Pharmaceuticals to Present at World Orphan Drug Congress USA in Washington DC

Tozaride Peptide Drug Shows Effectiveness in Small Cell Lung and Neuroendocrine Cancer
    BOSTON, MA, April 21, 2017 /24-7PressRelease/ -- Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the World Orphan Drug Conference in Washington, DC on April 21, 2017. Conference location and agenda information are available at the World Orphan Drug Congress.

About Tozaride
Tozaride is a novel, best-in-class therapy for lung and other cancers based on the radio-labeled somatostatin peptide Tozaride. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in heavily pre-treated advanced lung cancer patients. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC) patients, and which will provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.

About Andarix Pharmaceuticals
Andarix Pharmaceuticals is a clinical stage company developing targeted imaging and therapies for lung, neuroendocrine, and other cancers based on a proprietary somatostatin peptide conjugate. Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung cancers. Lung cancer is the leading cause of cancer mortality in the United States for both men and women. In 2016, there were an estimated 225,470 new diagnoses of non-small cell lung cancer (NSCLC) with 42,000 small cell lung cancer patients. To learn more about Andarix, please visit www.andarix.com.


# # #

Read more Press Releases from Christopher Adams:


Comment on this story...

Share This Story


Email this Story

Contact Information


Christopher Adams
Andarix Pharmaceuticals

Somerville, MA
USA
Voice: 617-957-9858
E-Mail: Email Us Here
Website: Visit Our Website

Like This Story?


I like it! 0

Disclaimer


If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release Newswire. We are unable to assist you with any information regarding this release. 24-7 Press Release Newswire disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.